ClinicalTrials.gg
CompletedNCT04504942Updated Jan 23, 2026Results posted

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

A Phase 2 interventional study of Leronlimab in Solid Tumor, Adult, sponsored by CytoDyn, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A single arm phase II study with 30 patients of leronlimab (PRO 140) in patients with CCR5+ locally advanced or metastatic solid tumors.

Read the detailed description

Leronlimab (PRO 140) will be administered subcutaneously as weekly dose of 525 mg until disease progression or intolerable toxicity. Subjects participating in this study will be allowed to receive/continue standard-of-care chemotherapy or radiotherapy as per the dosing schedule included on the package insert.

In this study, patients will be evaluated for tumor response approximately every 3 months or according to institution's standard practice by CT, PET/CT or MRI with contrast (per treating investigator's discretion) using the same method as at baseline.

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have a or cytologically confirmed diagnosis of locally advanced or solid tumors:

    1. who have disease progression on standard therapy,
    2. who are receiving a standard anticancer treatment but no subsequent approved treatment would be available upon progression,
    3. who are unable to receive standard therapy, or
    4. for whom standard therapy does not exist.
  2. Demonstrate CCR5 + by IHC (>10% of primary or metastatic tumor cells shows membranous staining and/or high predominance of CCR5+ tumor-infiltrating leukocytes completed at the reference laboratory of Dr. Hallgeir Rui at Medical College of Wisconsin).

    Note: This test will be done as part of the pre-screening period. It will be performed in archival metastatic tissue. If is not available then, fresh biopsy will be done;

  3. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion (in case archival tissue is not available);
  4. Patients must have based on v1.1;
  5. ≥ 18 years of age;
  6. Patients must exhibit a/an performance status of 0-1;
  7. of at least 6 months;
  8. Patients must have adequate organ and bone marrow function within 28 days prior to registration, as defined below:

    • leukocytes ≥ 3,000/mcL;
    • ≥ 1,500/mcL;
    • ≥ 100,000/mcL;
    • total : within normal institutional limits;
    • (SGOT) and ALT(SPGT) ≤ 2.5 X institutional (ULN) (applicable to all patients, irrespective of liver disease or metastasis); and
    • creatinine: within normal institutional limits.
  9. Clinically normal resting 12-lead at Screening Visit or, if abnormal, considered not by the Principal Investigator.
  10. Females of (FOCBP) and males must agree to use two medically accepted methods of with hormonal or barrier method of birth control, or abstinence, prior to study entry, for the duration of study participation and for 60 days after the last dose of study drug (Refer to Appendix 1). Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; and
    • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally for > 12 months).
  11. FOCBP must have a negative serum pregnancy test at Screening Visit and negative urine pregnancy test prior to receiving the first dose of study drug; and
  12. Patients must have the ability to understand and the willingness to sign a written prior to registration on study.

Exclusion criteria

Exclusion Criteria:

  1. Is currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 28 days prior to enrollment;
  2. Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (PRO 140) are not eligible;
  3. Patients who have had prior exposure to CCR5 antagonists are not eligible;
  4. Has known active central nervous system (CNS) and/or carcinomatous meningitis. Note: Subjects with previously treated may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability;
  5. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator;
  6. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; and
  7. Is pregnant or breastfeeding, or expecting to conceive or have children within the projected duration of the trial, starting with the pre-screening or screening visit through the duration of study participation.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Leronlimab 525mg

    Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

    Drug: Leronlimab

Interventions

  • Drug: Leronlimab 525mg

    Also known as: Standard-of-care chemotherapy or radiotherapy

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs).

    Adverse events were elicited through direct questioning and subject reports. Any abnormalities in visit evaluations, physical examination findings or laboratory results that the investigator believed were clinically significant to the research subject were reported as adverse events.

    Time frame: From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months)

  2. Changes in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Subsequent Scheduled Visits

    The ECOG was utilized to assess the ability of patients to tolerate treatment. The ECOG is a 5-point scale, where a higher score indicates a greater lack of tolerance of the treatment. Response choices included: 0 = Asymptomatic; Fully active, able to carry on all pre-disease performance without restriction, 1 = Symptomatic but completely ambulatory; Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2 = Symptomatic, \<50% in bed during the day; Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours, 3 = Symptomatic, \>50% in bed during the day; Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours, 4 = Bedbound; Completely disabled; cannot carry on any selfcare; totally confined to bed or chair, 5 = Dead.

    Time frame: From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months)

Secondary outcomes

  1. Progression Free Survival (PFS) Defined as Time in Months From the Date of First Study Treatment to the Date of Disease Progression or Death From Any Cause, Whichever Comes First.

    The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria was used for objective tumor response assessment (when disease is measurable and non- measurable); PFS is calculated from the date of first dose of leronlimab until date of clinical progressions.

    Time frame: The time in months from start of treatment to progression or death will be measured for all patients who receive at least one dose of study drug. Participants were followed on study until last study visit completion up to approximately 16 months.

  2. Overall Response Rate (ORR, Defined as CR (Complete Response) + PR (Partial Response)) in Subjects With CCR5+ Locally Advanced or Metastatic Solid Tumors Treated With Leronlimab.

    Overall response rate is defined as the percentage of patients who achieve an overall response of complete response or partial response in the total number of evaluable patients, assessed by RECIST v1.1.

    Time frame: The time in months from start of treatment to progression or death will be measured for all patients who receive at least one dose of study drug. Participants were followed on study until last study visit completion up to approximately 16 months.

  3. Mean Time to New Metastases (TTNM)

    Recorded time from baseline metastatic disease (at time of enrollment) to the time of development of new metastasis in different site. New metastases in same site will be also recorded. TTNM will be calculated according to the formula: TTNM=(Date of new metastases - Date of first treatment) + 1.

    Time frame: From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months).

  4. The Change From Baseline in Circulating Tumor Cells (CTC) Level in the Peripheral Blood.

    Reported unit of measure will be the number of CTCs/milliliters. CTCs enumeration will be performed at baseline and at the time of response assessment. Fraction of baseline positive and change from ≥5 CTCs will be recorded and reported.

    Time frame: From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first. From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months).

  5. Overall Survival Defined as Time in Months From the Date of First Study Treatment to the Date of Death

    Overall survival defined as time in months from the date of first study treatment to the date of death. Patients will be followed from the start of treatment (first dose) until long-term follow up date (up to 2 years post-treatment or death), whichever occurs first, and average survival time will be measured.

    Time frame: Overall survival is calculated by long-term follow-up date - PRO 140 (leronlimab) start date, up to approximately 57 months.

07

Results

Posted Jan 23, 2026

Participant flow

Participant flow — Overall Study
MilestoneLeronlimab 525mg
Started16
Completed6
Not completed10
Withdrew: Withdrawal by subject2
Withdrew: 7 patients were on-going at the time when study was closed by sponsor.7
Withdrew: Disease progression1

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs).

Adverse events were elicited through direct questioning and subject reports. Any abnormalities in visit evaluations, physical examination findings or laboratory results that the investigator believed were clinically significant to the research subject were reported as adverse events.

Time frame:
From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs).
ParticipantsLeronlimab 525mg
Adverse Events11
Serious Adverse Events3
PrimaryChanges in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Subsequent Scheduled Visits

The ECOG was utilized to assess the ability of patients to tolerate treatment. The ECOG is a 5-point scale, where a higher score indicates a greater lack of tolerance of the treatment. Response choices included: 0 = Asymptomatic; Fully active, able to carry on all pre-disease performance without restriction, 1 = Symptomatic but completely ambulatory; Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2 = Symptomatic, \<50% in bed during the day; Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours, 3 = Symptomatic, \>50% in bed during the day; Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours, 4 = Bedbound; Completely disabled; cannot carry on any selfcare; totally confined to bed or chair, 5 = Dead.

Time frame:
From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months)
Reported as:
Number · Participants
Changes in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Subsequent Scheduled Visits
ParticipantsLeronlimab 525mg
Participants with improved ECOG score2
Participants with stable ECOG score2
Participants with worsened ECOG score2
Missing data10
SecondaryProgression Free Survival (PFS) Defined as Time in Months From the Date of First Study Treatment to the Date of Disease Progression or Death From Any Cause, Whichever Comes First.

The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria was used for objective tumor response assessment (when disease is measurable and non- measurable); PFS is calculated from the date of first dose of leronlimab until date of clinical progressions.

Time frame:
The time in months from start of treatment to progression or death will be measured for all patients who receive at least one dose of study drug. Participants were followed on study until last study visit completion up to approximately 16 months.
Reported as:
Mean · months
Progression Free Survival (PFS) Defined as Time in Months From the Date of First Study Treatment to the Date of Disease Progression or Death From Any Cause, Whichever Comes First.
monthsLeronlimab 525mg
Progression Free Survival (PFS) Defined as Time in Months From the Date of First Study Treatment to the Date of Disease Progression or Death From Any Cause, Whichever Comes First.4.05 ± 2.758
SecondaryOverall Response Rate (ORR, Defined as CR (Complete Response) + PR (Partial Response)) in Subjects With CCR5+ Locally Advanced or Metastatic Solid Tumors Treated With Leronlimab.

Overall response rate is defined as the percentage of patients who achieve an overall response of complete response or partial response in the total number of evaluable patients, assessed by RECIST v1.1.

Time frame:
The time in months from start of treatment to progression or death will be measured for all patients who receive at least one dose of study drug. Participants were followed on study until last study visit completion up to approximately 16 months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR, Defined as CR (Complete Response) + PR (Partial Response)) in Subjects With CCR5+ Locally Advanced or Metastatic Solid Tumors Treated With Leronlimab.
percentage of participantsLeronlimab 525mg
Overall Response Rate (ORR, Defined as CR (Complete Response) + PR (Partial Response)) in Subjects With CCR5+ Locally Advanced or Metastatic Solid Tumors Treated With Leronlimab.18.2
SecondaryMean Time to New Metastases (TTNM)

Recorded time from baseline metastatic disease (at time of enrollment) to the time of development of new metastasis in different site. New metastases in same site will be also recorded. TTNM will be calculated according to the formula: TTNM=(Date of new metastases - Date of first treatment) + 1.

Time frame:
From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months).
Reported as:
Mean · days
Mean Time to New Metastases (TTNM)
daysLeronlimab 525mg
Mean Time to New Metastases (TTNM)286 ± 0
SecondaryThe Change From Baseline in Circulating Tumor Cells (CTC) Level in the Peripheral Blood.

Reported unit of measure will be the number of CTCs/milliliters. CTCs enumeration will be performed at baseline and at the time of response assessment. Fraction of baseline positive and change from ≥5 CTCs will be recorded and reported.

Time frame:
From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first. From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months).
Reported as:
Number · CTCs/milliliters
The Change From Baseline in Circulating Tumor Cells (CTC) Level in the Peripheral Blood.
CTCs/millilitersLeronlimab 525mg
The Change From Baseline in Circulating Tumor Cells (CTC) Level in the Peripheral Blood.22
SecondaryOverall Survival Defined as Time in Months From the Date of First Study Treatment to the Date of Death

Overall survival defined as time in months from the date of first study treatment to the date of death. Patients will be followed from the start of treatment (first dose) until long-term follow up date (up to 2 years post-treatment or death), whichever occurs first, and average survival time will be measured.

Time frame:
Overall survival is calculated by long-term follow-up date - PRO 140 (leronlimab) start date, up to approximately 57 months.
Reported as:
Mean · months
Overall Survival Defined as Time in Months From the Date of First Study Treatment to the Date of Death
monthsLeronlimab 525mg
Overall Survival Defined as Time in Months From the Date of First Study Treatment to the Date of Death53.60 ± 3.956

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were reported from the time of the first treatment and continued up until the final study visit (EOT visit) to evaluate safety of leronlimab (PRO 140) (up to approximately 16 months). All-cause mortality was assessed from first dose through the long-term follow-up period (up to approximately 57 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leronlimab 525mg12/16 (75%)3/16 (18.8%)11/16 (68.8%)
Most frequent serious events
Most frequent serious events
EventLeronlimab 525mg
SepsisInfections and infestations1/16
Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/16
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/16
Urinary retentionRenal and urinary disorders1/16
Most frequent other events
Showing 10 of 27
Most frequent other events
EventLeronlimab 525mg
ChillsGeneral disorders2/16
HeadacheNervous system disorders2/16
HypokalaemiaMetabolism and nutrition disorders2/16
Injection site reactionGeneral disorders2/16
InsomniaPsychiatric disorders2/16
NauseaGastrointestinal disorders2/16
AlopeciaSkin and subcutaneous tissue disorders1/16
AnxietyPsychiatric disorders1/16
ArthralgiaMusculoskeletal and connective tissue disorders1/16
ArthritisMusculoskeletal and connective tissue disorders1/16

Baseline characteristics

All patients who received at least one dose of leronlimab (PRO 140) were included in the baseline analysis population.

Age, Categorical
Age, Categorical(Participants)Leronlimab 525mg
<=18 years0
Between 18 and 65 years12
>=65 years3
Age, Continuous
Age, Continuous(years)Leronlimab 525mg
Mean54.87 ± 15.36
Sex: Female, Male
Sex: Female, Male(Participants)Leronlimab 525mg
Female8
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Leronlimab 525mg
Hispanic or Latino1
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Leronlimab 525mg
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Leronlimab 525mg
United States16
08

Study locations

1 site
  • Quest Clinical Research
    San Francisco, California 94115, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Nov 2021, 18 months.

Results were first posted in Jan 2026, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2020
First posted
Aug 7, 2020
StartActual
May 1, 2020
Primary completionActual
Nov 7, 2021
CompletionActual
Jan 27, 2025
Results first posted
Jan 23, 2026
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04504942
Lead sponsor
CytoDyn, Inc.
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Aug 7, 2020
Start date
May 1, 2020
Primary completion
Nov 7, 2021
Completion
Jan 27, 2025
Results posted
Jan 23, 2026
Last update
Jan 23, 2026

Study contacts

Jacob Lalezari, MD
study director · CytoDyn, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion